Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonic Acid SCHEMBL6672041 | 0.92 | KDM4C (0.39) | PKMMAPK1NPSR1KDM4ESLC6A3 | |
| SCHEMBL4779862 | 0.91 | PKM (0.42) | PKMMAPK1NPSR1KDM4ESLC6A3 | |
| SCHEMBL907879 | 0.82 | KDM4E (0.44) | PKMMAPK1NPSR1KDM4ESLC6A3 | |
| SCHEMBL4888615 | 0.81 | MAPK1 (0.41) | PKMMAPK1NPSR1KDM4ESLC6A3 | |
| SCHEMBL860903 | 0.80 | — | — | |
| SCHEMBL9079443 | 0.78 | KDM4C (0.42) | PKMMAPK1NPSR1KDM4ESLC6A3 | |
| SCHEMBL30223118 | 0.77 | KDM4C (0.47) | PKMMAPK1NPSR1KDM4EKDM4C | |
| SCHEMBL6303359 | 0.77 | MAPK1 (0.38) | PKMMAPK1NPSR1KDM4ESLC6A3 | |
| SCHEMBL6679679 | 0.77 | LMNA (0.38) | PKMMAPK1NPSR1KDM4ESLC6A3 | |
| SCHEMBL7270380 | 0.77 | TSHR (0.40) | PKMMAPK1NPSR1KDM4EKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379538-A2 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Orchid Research Laboratories Limited (IN) | 2011-10-26 | — | — | EP | claimed |
| WO-2010084402-A2 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-29 | — | — | WO | claimed |
| WO-2022226203-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-10-27 | — | — | WO | disclosed |
| US-8304577-B2 | Modulators of G protein-coupled receptor 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110251196-A1 | Modulators of G Protein-Coupled Receptor 88 | Bristol-Myers Squibb Company and Lexicon Pharmaceuticals, Inc. | 2011-10-13 | — | — | US | disclosed |
| US-7358276-B2 | for treating neurological disorders such as epilepsy, neuropathic pain, bipolar disorder or migraine; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; neuroprotective agent | UCB, S.A. (BE) | 2008-04-15 | — | — | US | disclosed |
| US-20050171188-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2005-08-04 | — | — | US | disclosed |
| EP-0439556-A4 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | — | 1991-10-30 | — | — | EP | disclosed |
| EP-0439556-A1 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1991-08-07 | — | — | EP | disclosed |
| WO-1990004917-A1 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1990-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171188-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | PKM 342/4885MAPK1 2113/4885NPSR1 583/4885 |
| US-20110251196-A1 | Modulators of G Protein-Coupled Receptor 88 | GPR88, GPR68, GRK2 | PKM 4366/4885MAPK1 2451/4885NPSR1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.